Standard analgesic practices for the treatment of central and peripheral neuropathic pain syndromes (including opioids, tricyclic antidepressants, anticonvulsants, NMDA receptor antagonists, and other ion channel antagonists) have thus far provided inadequate pain relief. Our focus is on the treatment of acute and chronic pain following peripheral nerve and spinal cord injuries, migraine, connective tissue disorders, and the arthritides, using drugs that are delivered orally, directly into the bloodstream, and directly into the spinal fluid. Our focus is on non-opioid analgesics.

Our studies investigate pain relief in peripheral and central neuropathic pain states by examining how novel drugs effect different pain mechanisms. Recent basic and clinical research with new drugs opens the possibility for new treatments. Our focus is on identifying selective causes of pain in individual patients and matching them with the therapies that are being evaluated in the appropriate clinical trials; we often use experimental pain models as tools.

If you are interested in participating or learning more about our research please contact us.

 

                  Sponsors of Our Research Have Included:

National Institute of Neurological Diseases and Stroke (National Institutes of Health)
Christopher Reeve Foundation
Mike Utley Foundation
Paralyzed Veterans of America
Lilly Research Laboratories
Endo Pharmaceuticals, Inc.
Pfizer, Inc.
Johnson & Johnson Subsidiaries
AstraZeneca
Schwarz Pharma
Cogentix, Inc.
Gedeon Richter Ltd.